A passive immunotherapy, PEHRG214, in patients infected with human immunodeficiency virus: A phase I study

Journal of Infectious Diseases

Volumn 187, Issue 3, 2003, Pages 500-503

  Dezube, Bruce J ^a,c   Proper, JoAnn ^a   Zhang, Jielin ^a   Choy, Vern J ^b   Weeden, William ^a   Morrissey, Janine ^a   Burns, Eve M ^a   Dixon, James D ^b   O'Loughlin, Christopher ^b   Williams, Lisa A ^b   Pickering, Paul J ^b   Crumpacker, Clyde S ^a   Gelder, Frank B ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Virionyx Corporation Ltd   (New Zealand)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY HRG214; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; IN VITRO STUDY; INHIBITION KINETICS; LYMPHOCYTE COUNT; MALE; PAPULE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RASH; URTICARIA; VIRUS LOAD;

ANIMALS; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; GOATS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; RNA, VIRAL;

EID: 0037317171     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/367710     Document Type: Article

References (11)

1. Robert-Guroff M, Brown M, Gallo R. HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985; 316:72-74.
2. Vittecoq D, Mattlinger B, Barr-Sinoussi F, et al. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis 1992; 165:364-8.
3. Blick G, Scott WF, Crook SW, et al. Passive immunotherapy in advanced HIV infection and therapeutic plasmapheresis in asymptomatic HIV-positive individuals: a four-year clinical experience. Biotherapy 1998; 11:7-14.
4. Vittecoq D, Chevret S, Morand-Joubert L. A double-blind randomized study based on transfusions of plasma rich in anti-HIV-1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995; 92:1195-9.
5. Karpas A, Hill F, Youle M, et al. Effects of passive immunization in patients with AIDS-related complex and AIDS. Proc Natl Acad Sci USA 1988; 85:9234-7.
6. Poignard P, Klasse PJ, Sattentau QJ. Antibody neutralization of HIV-1. Immunol Today 1996; 17:239-46.
7. Armbruster C, Stieglera GM, Vcelarb B, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002; 16:227-33.
8. 3 (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis 1998; 177:617-24.
9. Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank NN. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med 1984; 311:1407-13.
10. Trkola A, Pomales AB, Yuan H, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995; 69:6609-17.
11. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 4 February 2002. Available at: http://www.hivatis.org.